Summary of Assays for Lympho-Hematopoietic Stem, Progenitor and Precursor Cells from HemoGenix®
Colony-Forming Cell (CFC) Assays
CAMEO™-4 is a traditional methyl cellulose, clonogenic colony-forming cell (CFC) differentiation assay and the only CFC assay available in miniaturized format. CAMEO™-4 is available for at least 13 different cell populations from 6 species providing the user with the greatest flexibility to detect the differentiation status and/or potential from multiple cell populations.
CAMEO™-96 is the only methyl cellulose-based assay that allows the user to measure both proliferation and differentiation in the same sample. This unique, two-step signal detection system assay allows the user to count and identify differentiated colonies and then measure proliferation using the proprietary and patented HemoGenix® ATP-based bioluminescence readout developed for HALO®, LUMENESC™ and LumiSTEM™ Platforms.
HALO®-96 Research Assays
HALO®-96 Research is a methyl cellulose, clonogenic or Suspension Expansion Culture (SEC) proliferation assay for at least 10 different lympho-hematopoietic stem, progenitor and precursor cell populations derived from human, non-human primate, sheep, dog, rat and mouse. HALO®-96 using a patented, highly sensitive, reliable and reproducible instrument-based, ATP bioluminescence signal detection system.
HALO®-96 PREP is a variation of HALO®-96 Research that measures the proliferation, self-renewal and expansion potential of primitive, high proliferation potential stem and progenitor (HPP-SP) lympho-hematopoietic stem cells using a two-stage, "priming" and secondary re-plating technology.
HALO®-96 Quality Control, Potency and Patient Monitoring Assays for Cord Blood Banks and Stem Cell Transplantation
HALO®-96 SPC-QC is used to test stem cell "quality" of the and primitive and mature stem cells in a processed product before and/or after cryopreservation to ensure that the stem cells will proliferate prior to transplantation. HALO®-96 SPC-QC is for routine use with umbilical cord blood, bone marrow or mobilized peripheral blood.
HALO®-96 PQR (Potency, Quality, Release) is the first and only assay designed specifically for umbilical cord blood to establish the potency and quality of a processed product prior to transplantation in order to predict engraftment potential. HALO®-96 PQR also establishes acceptance (rejection) limits for release of a cord blood unit for transplantation purposes. HALO®-96 PQR was designed to be compliant with both European and future U.S. guidelines and regulations for umbilical cord blood potency testing. HALO®-96 PQR is available to measure the potency of mature stem cells alone or with primitive stem cells.
HALO®-96 PMT was designed to measure engraftment and repopulation of the lympho-hematopoietic system in patients after transplantation. HALO®-96 PMT is available to measure 4 or 7 lympho-hematopoietic stem and progenitor cell populations simultaneously thereby providing an overview of reconstitution.
Assays for Predicting Hemotoxicity and Drug Interaction
HemoGenix® is the leader in hemotoxicity testing
HemoGenix® is the only company that provides 384-well plate, high throughput (HT) predictive hemotoxicity screening for biopharmaceutical companies and environmental testing. HALO®-96 PHP (Predictive Hemotoxicity Platform) and HALO®-384 HT can be used at any stage of drug development, from high throughput ADMETox screening to patient monitoring during clinical trials. Both HALO®-96 PHP and HALO®-384 HT are available as contract research services or as assay kits for in-house implementation. Both platforms can be used to test the response to compounds on multiple cell populations and up to 5 species (human, non-human primate, dog, rat and mouse) simultaneously, thereby providing important toxicity ranking information.
HALO®-DDI (Drug-Drug Interaction) is the first 384-well plate, high throughput platform that provides information on the interaction of 2 or more drugs at a cellular level, rather than on the P450 cytochrome system. Lympho-hematopoietic stem cells are fully capable of metabolizing drugs, the effects of which can lead to important side effects.